Analyst at Numis Maintains hVIVO Plc (LON:HVO)Stock Rating as a ‘Buy’

June 18, 2018 - By Kurt Siggers

hVIVO plc (LON:HVO) Logo

hVIVO Plc (LON:HVO) Rating Reaffirmed

In an analyst report revealed to clients on 18 June, Numis reiterated their Buy rating on hVIVO Plc (LON:HVO) shares.

The stock increased 27.41% or GBX 5.4 during the last trading session, reaching GBX 25.1. About 179,210 shares traded or 27.68% up from the average. hVIVO plc (LON:HVO) has 0.00% since June 18, 2017 and is . It has underperformed by 12.57% the S&P500.

hVIVO plc, a specialty biopharma company, provides medical and scientific research services in the United Kingdom. The company has market cap of 19.63 million GBP. It is developing a human analytical platform to accelerate drug discovery and development in respiratory and infectious diseases, including flu, RSV, asthma, exacerbation, and common cold. It currently has negative earnings. The firm also offers laboratory based research services; and target and biomarker discovery services.

Another recent and important hVIVO plc (LON:HVO) news was published by which published an article titled: “Equities Research Analysts’ Updated EPS Estimates for June, 6th (AZN, BDEV, BT.A, FORT, HNT, HVO, KEYS, KLIC …” on June 06, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: